Combination therapy shows promising results in patients with rare subtype of non-Hodgkin lymphoma
Bottom line: Combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body’s natural response to viral infections, showed promising results in patients with relapsed or refractory natural killer/T-cell lymphoma (R/R NKTL), a rare and aggressive cancer with limited treatment options. Journal in which the study was published: Cancer Discovery, a journal of the American Association…
View On WordPress













